Anavex Life Sciences Corp. · NASDAQ:AVXL

Anavex Life Sciences — Conference Presentation (March 2016)

27 slides from Anavex Life Sciences's conference presentation, Mar 12, 2016

  1. Slide 1: AAT Presentation

    Slide 1: AAT Presentation

    NASDAQ: AVXL AAT Presenta3on Christopher U. Missling, PhD President & CEO 2016

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presenta,on contains forward-­‐looking statements made within the meaning of the Private Securi,es Li,ga,on Reform Act of 1995 by Anavex™ Life Sciences Corp. and its representa,ves. These statements can be iden,fied by introductory words such as ``expects,'' ``plans,'' ``intends,'' `

  3. Slide 3: Anavex Mission

    Slide 3: Anavex Mission

    Anavex™ Mission Developing Differen,ated Therapeu,cs for the Treatment of Neurodevelopmental and Neurodegenera,ve Diseases 3

  4. Slide 4: ANAVEX 2-73: Confirmed Targeted Indications

    Slide 4: ANAVEX 2-73: Confirmed Targeted Indications

    ANAVEX™ 2-­‐73: Confirmed Targeted Indica3ons: From Rare Disease Indica3on to Largest CNS Indica3on … ReW Syndrome (RTT) Alzheimer’s Disease (AD) Rare neurodevelopmental disease Neurodegenera,ve disease Preclinical valida,on þ Clinical valida,on Phase 2a þ Planning blinded controlled Phase 2 ☐ Plan

  5. Slide 5: Sigma-1 R Resolving Protein Misfolding Caused by ER Stress

    Slide 5: Sigma-1 R Resolving Protein Misfolding Caused by ER Stress

    Sigma-­‐1 R Resolving Protein Misfolding Caused by ER Stress ANAVEX 2-­‐73 § Addi3onal Therapeu3c’s Poten3al Mode of Ac3on -­‐ mixed muscarinic / Sigma-­‐1R agonist targe3ng: − Calcium (Ca2+) modula,on − Mitochondrial dysfunc,on − Reducing oxida,ve stress − Reducing inflamma,on − Reducing A-­‐beta a

  6. Slide 6: Sigma-1 R: Pluripotent Modulator Against Chronic Stress

    Slide 6: Sigma-1 R: Pluripotent Modulator Against Chronic Stress

    Sigma-­‐1 R: Pluripotent Modulator Against Chronic Stress Monomer Chronically Distressed Cell: Healthy Cell: Misfolded Proteins Quick Removal Sigma-­‐1R Aber U3liza3on Helping / S3mula3ng Ca2+ dysfunc,on ANAVEX 2-73 Own Body to Aß plays Regain important role in hippocampal Func3onality – memory Mito

  7. Slide 7: ANAVEX 2-73 Efficient Clinical Trial Execution Plan

    Slide 7: ANAVEX 2-73 Efficient Clinical Trial Execution Plan

    ANAVEX™ 2-­‐73 Efficient Clinical Trial Execu3on Plan ANAVEX™2-­‐73-­‐001 Study: •Phase 1 (oral) Completed •Single Ascending Dose (SAD) •Healthy subjects ANAVEX™2-­‐73-­‐002 Study: •Phase 2a (oral) PART A: Preliminary Data Nov CTAD 2015 •Mild-­‐to-­‐moderate AD pa,ents PART A: Dose-­‐Response •Adap,ve

  8. Slide 8: Proof of Concept Study: ANAVEX 2-73 Protocol Summary

    Slide 8: Proof of Concept Study: ANAVEX 2-73 Protocol Summary

    Proof of Concept Study: ANAVEX 2-­‐73 Protocol Summary ▪ Phase 2a study of 32 pa,ents with mild-­‐moderate AD ▪ 5 weeks’ dura,on, randomized, open-­‐label, adap,ve design, dosing regimen without dose op,miza,on ▪ Main inclusion criteria ▪ Baseline MMSE 16-­‐28 ▪ CT or MRI within 12 months consistent

  9. Slide 9: ANAVEX 2-73: Phase 2a with Adaptive Trial Design

    Slide 9: ANAVEX 2-73: Phase 2a with Adaptive Trial Design

    ANAVEX 2-­‐73: Phase 2a with Adap3ve Trial Design ANAVEX 2-­‐73 star,ng dose 30mg/50mg (oral) or 3mg, 5mg (IV) ANAVEX 2-­‐73 star,ng dose 30mg/50mg (oral) or 3mg, 5mg Mild-­‐Mod AD pa,ents (IV) + Donepezil Donepezil/ AchEI# No. of Pts: § 32 mild-­‐moderate AD pa,ents (MMSE 16-­‐28), M/F = 19/13 Sit

  10. Slide 10: Baseline Patient Characteristics and Disposition

    Slide 10: Baseline Patient Characteristics and Disposition

    Baseline Pa3ent Characteris3cs and Disposi3on * Donepezil 10

  11. Slide 11: Part A Cross-Over Design and Part B 52-Week Extension

    Slide 11: Part A Cross-Over Design and Part B 52-Week Extension

    PART A: Bioavailability Cross-­‐Over Design and PART B: 52-­‐Week Open-­‐Label Voluntary Extension ORAL ORAL ORAL Screening Randomiza,on ORAL IV IV IV wash out 12d 12d 12d 5 week 26 week 52 week 1st Period 2nd Period [,me] Part A Completed Ongoing Part B PK - Study Extension ▪ Once daily oral or IV

  12. Slide 12: ANAVEX 2-73 Safety from Phase 2a

    Slide 12: ANAVEX 2-73 Safety from Phase 2a

    ANAVEX™ 2-­‐73 Safety from Phase 2a § Safety profile § The most common AE was dizziness followed by headache § Events were mild or moderate and reversible with 80% being grade 1 § There were no drug related AEs Grade 3, 4 and 5 § Most (94.4%) observed within first 8 days § AE profile similar to t

  13. Slide 13: Fast Onset of Action of Sigma-1 Receptor Agonist

    Slide 13: Fast Onset of Action of Sigma-1 Receptor Agonist

    Fast Onset of Ac3on of Sigma-­‐1 Receptor Agonist § Sigma-­‐1 agonists increase markedly serotonin (5-­‐HT) neurons firing ac,vity aoer 2 days of treatment and maintained the same increased firing rate aoer long-­‐term (21 days) treatment Br. J. Pharmacol. 2001;134:691–699; Curr Neuropharmacol. 2008

  14. Slide 14: Summary Dose-Response Analysis

    Slide 14: Summary Dose-Response Analysis

    Summary Dose-­‐Response Analysis § Pre-­‐planned analysis § Collected data includes both efficacy and safety: § Efficacy: MMSE and ERP (paired for each pa,ent, baseline and 5 week) § Safety: graded AEs for each pa,ent § Depend on several factors: § Binary: Low-­‐High dose, Sex, ApoE4; Con,nuous: B

  15. Slide 15: Quantitative Dose-Response Analysis

    Slide 15: Quantitative Dose-Response Analysis

    Quan3ta3ve Dose-­‐Response Analysis § The change in Mini Mental State Examina,on score (MMSE-­‐Δ) (MMSE difference recorded for every single study subject at the beginning and the end of the 5 week period) as a func,on of ANAVEX 2-­‐73 dose was examined using linear regression analysis § 32 pa,ents

  16. Slide 16: MMSE-Δ vs. ANAVEX 2-73 Dose

    Slide 16: MMSE-Δ vs. ANAVEX 2-73 Dose

    MMSE-­‐Δ (Delta) vs. ANAVEX 2-­‐73 Dose § Slope = 0.1418 95% CI = 0.0527-­‐0.2309 § Posi3ve slope with increased ANAVEX 2-­‐73 dose § Indicates a significant effect on MMSE-­‐Δ § A minimum dose of 14 mg AV2-­‐73 required to achieve a therapeu,c effect and to keep MMSE MMSE Δ-score score unchanged §

  17. Slide 17: EEG/P300/ERP Highlights Target Engagement of ANAVEX 2-73

    Slide 17: EEG/P300/ERP Highlights Target Engagement of ANAVEX 2-73

    EEG/P300/ERP Highlights Target Engagement of ANAVEX 2-­‐73 and Poten3al Correla3on with Cogni3ve Effect on a Cellular Level P300 Amplitude (µV) Task Accuracy (%) False Alarms (%) Reac,on Time (ms) Baseline 5.99±0.58 83.8±.3.9 3.4±1.0 559.0±24.0 Week 5 7.09±0.72 92.6±2.4 1.0±0.5 492.6±23.8* Healthy Co

  18. Slide 18: P300/ERP-Δ vs. ANAVEX 2-73 Dose

    Slide 18: P300/ERP-Δ vs. ANAVEX 2-73 Dose

    P300/ERP-­‐Δ (Delta) vs. ANAVEX 2-­‐73 Dose § Slope = 0.055 95% CI = 0.012-­‐0.098 (AV2-­‐73 alone) § Slope = 0.155 95% CI = 0.019-­‐0.029 (AV2-­‐73 with 10mg donepezil) § Posi3ve slopes with increased ANAVEX 2-­‐73 dose § Indicates a significant effect on ERP-­‐Δ P300/ERP Δ-score AV2-­‐73 with do

  19. Slide 19: Computerized Cogstate Test Battery

    Slide 19: Computerized Cogstate Test Battery

    Computerized Cogstate Test BaWery Cogstate’s test baNery for Alzheimer’s disease measures the following core cogni,ve domains: §Processing speed è Detec,on Test §ANen,on è Iden,fica,on Test §Working memory è One Back Test §Visual learning è One Card Learning Test §Verbal learning èInterna,o

  20. Slide 20: ANAVEX 2-73 Significantly Improves Components of Cogstate Tasks at Week 5

    Slide 20: ANAVEX 2-73 Significantly Improves Components of Cogstate Tasks at Week 5

    ANAVEX 2-­‐73 Significantly Improves Components of Cogstate Tasks at Week 5: Change from Baseline Cogni3ve Decline Cogni3ve Improvement Magnitude of Effect Size (d) change from baseline *p<0.05, **p<0.001 20

  21. Slide 21: Comparable Baseline of SoC (AIBL-AD) and ANAVEX 2-73 Trial

    Slide 21: Comparable Baseline of SoC (AIBL-AD) and ANAVEX 2-73 Trial

    Comparable Baseline of SoC (AIBL-­‐AD) and ANAVEX 2-­‐73 Trial SoC (Standard of Care) data from Australian Imaging Biomarkers and Lifestyle (AIBL-­‐AD#) study tes,ng Cogstate baNery in Alzheimer’s disease pa,ents Baseline data: SoC (AIBL-­‐AD) AV 2-­‐73 Par,cipants (n) 43 32 Age (mean) 79.6 71 MMSE

  22. Slide 22: Cogstate Test: Standardized Change Compared to SoC

    Slide 22: Cogstate Test: Standardized Change Compared to SoC

    Cogstate Test: ANAVEX 2-­‐73 Standardized Change from Baseline to 5 Week Compared to 4 Week SoC (AIBL-­‐AD#) Cogni,ve Cogni,ve Decline Improvement Detec,on 0.33 * Iden,fica,on 0.40* One Back 0.86** Visual Learning ISLT ISLT-­‐delay *p<0.05, **p<0.001 Standard devia,on difference to AIBL study at same

  23. Slide 23: Part B: 52-Week Open-Label Extension & New 104 Week Study

    Slide 23: Part B: 52-Week Open-Label Extension & New 104 Week Study

    PART B: 52-­‐Week Open-­‐Label Extension & New 104 Week Study ORAL ORAL/IV Screening Randomiza,on ORAL ORAL ORAL IV/ORAL 5 week 52 week 104 week [,me] Part A Part B PK Study - completed Extension - ongoing 23

  24. Slide 24: Interim Part B Data: Effect on ADCS-ADL at Week 12

    Slide 24: Interim Part B Data: Effect on ADCS-ADL at Week 12

    Interim PART B Data: Posi3ve Effect of ANAVEX 2-­‐73 on ADCS-­‐ADL at Week 12 70.00 68.00 66.00 Δ = +3.21 points ADCS-ADL score 64.00 62.00 60.00 58.00 ADCS-ADL (Baseline PART B) ADCS-ADL (Week 12) § Interim data: ANAVEX 2-­‐73 improved ADCS-­‐ADL signal in 11 out of 14 (78.6%) pa,ents Macfarlane et

  25. Slide 25: Summary

    Slide 25: Summary

    Summary § Phase 2a (PART A) results demonstrate a favorable safety, bioavailability, dose-­‐response curve and tolerability/risk profile § Despite the rela,ve small sample size of this proof-­‐of-­‐concept randomized open-­‐label study, dose-­‐response analysis seem to indicate a cogni,ve benefit as

  26. Slide 26: Future Development

    Slide 26: Future Development

    Future Development § Phase 2a PART B 52 week extension trial is ongoing § New Extension study of Phase 2a will allow collec,on of further safety data of up to 104 weeks § Phase 2a Popula,on PK/PD and PART B data will be presented once available § Guidance received from the FDA supports the Compa

  27. Slide 27: Contact Us

    Slide 27: Contact Us

    Contact Us Corporate Office: Anavex™ Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 (212) 332 4449 Shareholder & Media Rela3ons: Toll-­‐free: 1-­‐866-­‐505-­‐2895 Email: ir@anavex.com www.anavex.com NASDAQ: AVXL ANAVEX is a trademark of Anavex Life Sciences Corp. 27

Source: Internet Archive copy of anavex.com

More decks from Anavex Life Sciences Corp.

All 35 Anavex Life Sciences decks